TICKERNERD
Menu
CVSCVSHealthcare · Healthcare Plans

CVS Stock Forecast: CVS Health Corp. Price Predictions for 2026-2027

Last close, 4 Nov 2026
$80
−12.48% on the day

The 27 Wall Street analysts covering CVS Health Corp. hold a median 12-month price target of $113 — +41.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 79 of 100 as at 4 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$117.0B
Ticker Nerd rank
79/ 100
Median analyst target
$113
Analysts covering
27
Revenue$106.1B+7.3% y/y
Operating income$4.7B
Net income$3.0B
Free cash flow$5.7B
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−11.1%
1M
−6.8%
YTD
+3.9%
1Y
+5.6%
From 52W high
−26.7%
From 52W low
+16.7%
$69
$109
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CVS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores CVS Health Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 4 Nov 2026
79/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
87
Issuance
86
Growth
84
Value
80
Revisions
76
Accruals
69
Momentum
59
Quality
31
Size
3

Volatility (87): The share price has been relatively steady.

Quality (31): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Size (3): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

CVS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CVS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$60$80$100$120$140$160Jan 26Apr 26Jul 26Oct 26CVSHigh $146Median $113Low $103

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says27 analysts
25 Buy2 Hold0 Sell
Low $103Median $113High $146

The green dot is the last close — the median target sits +41.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 7 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
12 Oct 2026Leerink PartnersMaintainsOutperform$119 → $112
3 Sept 2026UBSMaintainsBuy$126 → $118
3 Sept 2026UBSMaintainsBuy—
19 Aug 2026Argus ResearchMaintainsBuy$104 → $114
19 Aug 2026Argus ResearchMaintainsBuy—
12 Aug 2026JP MorganMaintainsOverweight$111 → $118
12 Aug 2026JP MorganMaintainsOverweight—
6 Aug 2026BarclaysMaintainsOverweight$106 → $108
6 Aug 2026BarclaysMaintainsOverweight—
6 Aug 2026Evercore ISI GroupMaintainsOutperform—
6 Aug 2026Evercore ISI GroupMaintainsOutperform$130 → $125
6 Aug 2026UBSMaintainsBuy—
6 Aug 2026UBSMaintainsBuy$122 → $126
25 July 2026UBSMaintainsBuy—
24 July 2026UBSMaintainsBuy$115 → $122
14 July 2026Truist SecuritiesMaintainsBuy—
14 July 2026Truist SecuritiesMaintainsBuy$108 → $118
13 July 2026Wells FargoMaintainsOverweight—
13 July 2026Wells FargoMaintainsOverweight$103 → $123
9 July 2026RBC CapitalMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

CVS appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

CVS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Nov 2026, CVS Health Corp. returned +5.6% against +14.8% for the S&P 500, dividends included.

CVS vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130140Jan 26Apr 26Jul 26Oct 26CVSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CVS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
+7.9%
Analysts raising
3
Analysts cutting
2
Fundamentals

CVS Health Corp. (CVS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
24.1×

Cheaper than 31% of US stocks

Price / sales
0.3×

Cheaper than 88% of US stocks

Price / book
1.5×

Cheaper than 53% of US stocks

EV / EBITDA
10.5×

Cheaper than 35% of US stocks

Growth & margins
Revenue growth (YoY)
7.1%

Higher than 45% of US stocks

Earnings growth (YoY)
191.8%

Higher than 90% of US stocks

Gross margin
14.8%

Higher than 14% of US stocks

Operating margin
3.9%

Higher than 52% of US stocks

Net margin
1.2%

Higher than 50% of US stocks

Returns & dividend
Return on equity
6.2%

Higher than 55% of US stocks

Return on assets
3.0%

Higher than 65% of US stocks

Dividend yield
2.9%

Higher than 86% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

CVS Health Corp. (CVS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • CVS Health Corp. has a market value of $117.0B and an enterprise value of $175.7B.

  • Revenue in the twelve months to 30 June 2026: $415.1B. The latest quarter grew 7.1% year on year.

  • Net income over the same four quarters: $4.9B, a 1.2% net margin.

  • Diluted earnings per share, trailing twelve months: $3.78.

  • Free cash flow in the twelve months to 30 June 2026: $11.8B.

  • CVS Health Corp. spent $3.4B on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 1.3B.

  • Trailing P/E: 24.1×; forward P/E: 10.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 2.91%, paying out 70% of earnings.

  • CVS Health Corp. employs 219,000 people — $1.9M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 5 Nov 2026

Data provided by Twelve Data

Peers

CVS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHealthcare Plans
CompanyMarket capTKN rank
CVSCVS Health Corp.$117.0B79
ELVElevance Health, Inc.$96.5B77
CIThe Cigna Group$80.7B77
HUMHumana, Inc.$50.2B51
CNCCentene Corp.$37.4B93
UNHUnitedHealth Group, Inc.$370.8B81
MOHMolina Healthcare, Inc.$11.8B34

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own CVS Health Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CVS news & analysis

Inside CVS Health, a small group of top executives spent months engaged in a strategic review that developed into a secret plan: a decision to split up the $400 billion healthcare giant

WSJ · 5 Nov 2026negative

CVS Health is splitting its drugstore and insurance businesses after a months-long strategic review by a small group of top executives. The plan developed amid mounting regulatory pressure.

Why it matters — The separation could reshape CVS’s business structure, making it a significant development for company watchers.

Wednesday's Final Takeaways: CVS Splitting in Two, ORCL Scraps Tencent Deal

Schwab Network · 4 Nov 2026neutral

CVS Health will divide its healthcare empire into two separate businesses. The item also reports that Oracle scrapped its tentative deal with Tencent.

Why it matters — The planned division is a significant organizational change for CVS that may interest investors following the company.

CVS Health plans to split itself up. Here's why a breakup could make sense now

CNBC · 4 Nov 2026neutral

CVS Health plans to separate into two publicly traded companies by the first half of 2028, splitting its pharmacy business from Aetna and Caremark. Analysts say the pharmacy business and other units may be strong enough to stand alone after a roughly two-year turnaround.

Why it matters — The planned breakup would reshape CVS's business structure and separate its pharmacy operations from its insurer and pharmacy benefit manager.

CVS Dismantling Healthcare Empire: Regulatory Tailwinds v. Cost Headwinds

Schwab Network · 4 Nov 2026neutral

CVS Health plans to separate its retail pharmacy and insurance businesses. Jefferies healthcare analyst Brian Tanquilut says the move could help the company adapt to regulatory change.

Why it matters — The planned separation and its potential to support adaptation to regulatory change are relevant to CVS watchers.

FAQ

Frequently asked questions about CVS stock

What is the CVS stock price forecast for 2026-2027?

The 27 Wall Street analysts covering CVS Health Corp. have a median 12-month price target of $113, with estimates ranging from $103 to $146. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CVS stock a buy right now?

Of the 27 analysts covering CVS Health Corp., 25 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CVS Health Corp. 79 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CVS?

As at 4 Nov 2026, CVS Health Corp. ranks 79 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (87 of 100).

Will CVS stock go up?

No one can know that. What the data says: the median 12-month target from 27 analysts implies +41.3% from the last close, and Ticker Nerd's factor model ranks CVS Health Corp. 79 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CVS stock forecast for 2030?

No analyst covering CVS Health Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CVS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $103 to $146 over the next 12 months.

How has CVS stock performed over the past year?

CVS Health Corp. returned +5.6% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does CVS Health Corp. do?

CVS Health Corporation Common Stock represents ownership in CVS Health Corporation, a U.S. health solutions company headquartered in Woonsocket, Rhode Island.

What is the latest news on CVS?

The most recent item we track (WSJ, 5 Nov 2026): "Inside CVS Health, a small group of top executives spent months engaged in a strategic review that developed into a secret plan: a decision to split up the $400 billion healthcare giant". CVS Health is splitting its drugstore and insurance businesses after a months-long strategic review by a small group of top executives. The plan developed amid mounting regulatory pressure.

Company

About CVS Health Corp.

CVS Health Corporation Common Stock represents ownership in CVS Health Corporation, a U.S. health solutions company headquartered in Woonsocket, Rhode Island. The company operates across health care benefits, health services, pharmacy, and consumer wellness, serving members, patients, employers, health plans, and public-sector clients. Its businesses include health insurance and managed care services, pharmacy benefit management, retail and specialty pharmacy operations, and a broad range of consumer-facing health and wellness services. CVS Health also supports medication access, clinical care, and coordinated care delivery through integrated offerings that connect insurers, pharmacies, and care services. As a large diversified health care enterprise, CVS Health plays an important role in the U.S. health system by linking coverage, pharmacy services, and patient care in one integrated platform.

CEO Mr. J. David Joyner CEBS · 219,000 employees · United States · https://www.cvshealth.com